image header

News Releases

News Releases

Oct 21, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Read more

Oct 7, 2021

ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio Read more

Oct 5, 2021

Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (ALX148) in Patients with Advanced HER2-Expressing Breast Cancer and Other Solid Tumors Read more

Oct 1, 2021

ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Read more

Sep 16, 2021

ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent and Aggressive Non-Hodgkin Lymphoma Read more

Sep 7, 2021

ALX Oncology Announces Upcoming Virtual Investor Conference Participation Read more

Aug 12, 2021

ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights Read more

Jul 28, 2021

ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pembrolizumab) and Chemotherapy for the Treatment of Patients with Advanced Head and Neck Squamous Cell Carcinoma Read more

Jul 3, 2021

ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Robust Objective Response in Patients with Gastric or Gastroesophageal Junction Cancer Read more

Jun 14, 2021

ALX Oncology Announces Update on ASPEN-03 and ASPEN-04, the ALX148 Phase 2 Head and Neck Cancer Studies Read more

Displaying 1 - 10 of 22